Semaglutide (20 mg)
All products are 100% genuine and sourced from trusted manufacturers, with authenticity that can be verified for complete peace of mind.
Order exactly what you need with no minimum quantity required, whether it’s a single unit or a larger order.
Your order is guaranteed to arrive safely, with full shipment tracking and dedicated support to ensure a smooth delivery experience.
Your payments are protected with industry-standard encryption and trusted payment providers, ensuring every transaction is safe, private, and secure.
99% PURITY GUARANTEE
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC). Full analytical reports are available in the Certificate of Analysis section.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
This product is intended for research use only. It is not for human or veterinary use, not for diagnostic or therapeutic purposes, and should only be handled by qualified professionals.
Strength: 20 mg
CAS: 910463-68-2
Chemical Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight: 4113.6 g/mol
Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
Synonyms: NN9535
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.
Semaglutide is a synthetic GLP-1 receptor agonist analog supplied as a high-purity lyophilized peptide for laboratory research. It is widely studied in metabolic and endocrine research models to investigate glucose regulation, hormone signaling, and receptor-mediated cellular responses under controlled experimental conditions.
-
Cold chain shipping available for temperature-sensitive products.
-
Orders are processed within 1–2 business days.
-
Delivery timelines vary by destination and shipping method — view our Shipping Policy for region-specific estimates.
-
Tracking information will be provided once shipped.
-
No order minimum applies.
-
If your shipment is delayed, lost, or arrives damaged, you're covered under our Refund & Replacement Policy.
We accept Visa, Mastercard, and American Express. Apple Pay and Google Pay are available upon request via your account manager.
All transactions are processed through a secure, PCI DSS–compliant system to ensure your data is fully protected.
Why Choose NOVERA COMPOUNDS Peptides?
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Why Choose Medica Depot
Shop hundreds of medical products with no minimums and free shipping on large orders.
INFORMATION
What is Semaglutide (20 mg)?
Semaglutide (20 mg) is a synthetic peptide commonly studied in metabolic and endocrine research. It is a modified analog of glucagon-like peptide-1 (GLP-1), involved in glucose signaling and metabolic regulation.
This peptide has specific structural modifications, including an amino acid change and the addition of a fatty acid side chain. These modifications enhance its stability and prolong its interaction with receptors in experimental systems, distinguishing it from native GLP-1, which is rapidly degraded in the body.
Semaglutide (20 mg) is ideal for extended research workflows, repeated assays, and large experimental series that require a steady supply of peptide material. This product is strictly for laboratory research use.
Product Specifications
- CAS Number: 910463-68-2
- Synonym: NN9535
- Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
- Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular Weight:6 g/mol
- Purity: ≥95% (verified by HPLC and mass spectrometry)
- Packaging Format: 20 mg lyophilized powder in sealed research-grade vial
- Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
- Intended Use: For Laboratory Research Use Only
Key Characteristics of Semaglutide (20 mg)
- Synthetic GLP-1 receptor agonist analog designed for controlled research
- Structural modifications improve resistance to rapid enzymatic breakdown in experimental models
- Fatty acid side-chain enhances receptor interaction duration in vitro
- High purity verified through HPLC and mass spectrometry
- Supplied as a lyophilized powder to maintain integrity before reconstitution
- Suitable for metabolic, endocrine, and receptor-signaling research
- Compatible with standard peptide preparation, dilution, and assay methods
How Semaglutide (20 mg) Supports Research
Semaglutide (20 mg) is widely used to study GLP-1 receptor-mediated signaling and related metabolic pathways. Researchers use this peptide to explore receptor activation, second-messenger cascades (e.g., cAMP production), and downstream effects on cellular metabolism in controlled laboratory and preclinical environments.
With its enhanced stability compared to native GLP-1, Semaglutide facilitates the investigation of prolonged receptor engagement and time-dependent signaling responses. It is particularly useful for studying receptor desensitization, sustained signaling pathway activation, and for comparative studies with other GLP-1 receptor agonists.
Research Applications & Usage Information
Semaglutide (20 mg) is typically used in laboratory research focused on:
- GLP-1 receptor binding and activation assays
- Incretin hormone signaling pathway studies
- Glucose metabolism and endocrine regulation
- Cellular signaling and second-messenger pathway analysis
- Comparative studies of short-acting vs. long-acting GLP-1 analogs
- Preclinical metabolic model research
All applications are investigational and limited to controlled laboratory settings.
Handling and Storage Recommendations
- Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light.
- Keep vials tightly sealed when not in use.
- Minimize exposure to moisture and direct light during handling.
- Allow vials to equilibrate before opening to prevent condensation.
- After reconstitution, store solutions at 2–8 °C according to laboratory protocols.
- Avoid repeated freeze-thaw cycles to support research applications.
Research Use Only Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155
What is Semaglutide (20 mg)?
Semaglutide (20 mg) is a synthetic peptide commonly studied in metabolic and endocrine research. It is a modified analog of glucagon-like peptide-1 (GLP-1), involved in glucose signaling and metabolic regulation.
This peptide has specific structural modifications, including an amino acid change and the addition of a fatty acid side chain. These modifications enhance its stability and prolong its interaction with receptors in experimental systems, distinguishing it from native GLP-1, which is rapidly degraded in the body.
Semaglutide (20 mg) is ideal for extended research workflows, repeated assays, and large experimental series that require a steady supply of peptide material. This product is strictly for laboratory research use.
Product Specifications
- CAS Number: 910463-68-2
- Synonym: NN9535
- Peptide Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
- Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉
- Molecular Weight:6 g/mol
- Purity: ≥95% (verified by HPLC and mass spectrometry)
- Packaging Format: 20 mg lyophilized powder in sealed research-grade vial
- Storage Conditions: Store 2–8 °C (≤–20 °C long term). Protect from light.
- Intended Use: For Laboratory Research Use Only
Key Characteristics of Semaglutide (20 mg)
- Synthetic GLP-1 receptor agonist analog designed for controlled research
- Structural modifications improve resistance to rapid enzymatic breakdown in experimental models
- Fatty acid side-chain enhances receptor interaction duration in vitro
- High purity verified through HPLC and mass spectrometry
- Supplied as a lyophilized powder to maintain integrity before reconstitution
- Suitable for metabolic, endocrine, and receptor-signaling research
- Compatible with standard peptide preparation, dilution, and assay methods
How Semaglutide (20 mg) Supports Research
Semaglutide (20 mg) is widely used to study GLP-1 receptor-mediated signaling and related metabolic pathways. Researchers use this peptide to explore receptor activation, second-messenger cascades (e.g., cAMP production), and downstream effects on cellular metabolism in controlled laboratory and preclinical environments.
With its enhanced stability compared to native GLP-1, Semaglutide facilitates the investigation of prolonged receptor engagement and time-dependent signaling responses. It is particularly useful for studying receptor desensitization, sustained signaling pathway activation, and for comparative studies with other GLP-1 receptor agonists.
Research Applications & Usage Information
Semaglutide (20 mg) is typically used in laboratory research focused on:
- GLP-1 receptor binding and activation assays
- Incretin hormone signaling pathway studies
- Glucose metabolism and endocrine regulation
- Cellular signaling and second-messenger pathway analysis
- Comparative studies of short-acting vs. long-acting GLP-1 analogs
- Preclinical metabolic model research
All applications are investigational and limited to controlled laboratory settings.
Handling and Storage Recommendations
- Store at 2–8 °C (≤–20 °C for long-term storage). Protect from light.
- Keep vials tightly sealed when not in use.
- Minimize exposure to moisture and direct light during handling.
- Allow vials to equilibrate before opening to prevent condensation.
- After reconstitution, store solutions at 2–8 °C according to laboratory protocols.
- Avoid repeated freeze-thaw cycles to support research applications.
Research Use Only Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. doi:10.1021/acs.jmedchem.5b00726
- Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Published 2019 Apr 12. doi:10.3389/fendo.2019.00155




